Tianguangshi’s new drug marketing authorization application for MIL62 for the treatment of primary membranous nephropathy has been accepted
October 13, 2025
Source: drugdu
106
According to a report from People's Finance on October 12th, Beijing Yizhuang WeChat account, Beijing Tianguangshi Biotechnology Co., Ltd. (hereinafter referred to as "Tianguangshi"), a company in Beijing Economic and Technological Development Zone (Beijing Yizhuang), recently announced that its independently developed innovative third-generation CD20 antibody MIL62 for the treatment of primary membranous nephropathy (PMN) has been accepted by the National Medical Products Administration. It is reported that this is the world's first drug to be approved for the treatment of PMN. Its breakthrough not only provides a better treatment option for PMN, but also demonstrates China's innovative drug development.Leading advantages in drug research and development and industrialization.
https://finance.eastmoney.com/a/202510123531477277.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
